Botanix Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Botanix Pharmaceuticals has been growing earnings at an average annual rate of 10.3%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 25% per year.
Key information
10.3%
Earnings growth rate
20.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -25.0% |
| Return on equity | -12.8% |
| Net Margin | -670.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Botanix Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -14 | 11 | 0 |
| 31 Mar 24 | 1 | -12 | 9 | 0 |
| 31 Dec 23 | 0 | -10 | 7 | 0 |
| 30 Sep 23 | 2 | -10 | 6 | 0 |
| 30 Jun 23 | 4 | -9 | 6 | 0 |
| 31 Mar 23 | 5 | -10 | 6 | 0 |
| 31 Dec 22 | 6 | -11 | 6 | 0 |
| 30 Sep 22 | 5 | -12 | 5 | 0 |
| 30 Jun 22 | 3 | -13 | 5 | 0 |
| 31 Mar 22 | 1 | -12 | 4 | 0 |
| 31 Dec 21 | 0 | -11 | 4 | 0 |
| 30 Sep 21 | 3 | -7 | 3 | 0 |
| 30 Jun 21 | 7 | -3 | 3 | 0 |
| 31 Mar 21 | 7 | -6 | 4 | 0 |
| 31 Dec 20 | 7 | -9 | 5 | 0 |
| 30 Sep 20 | 7 | -13 | 8 | 0 |
| 30 Jun 20 | 8 | -17 | 10 | 0 |
| 31 Mar 20 | 8 | -18 | 10 | 0 |
| 31 Dec 19 | 8 | -20 | 10 | 0 |
| 30 Sep 19 | 6 | -18 | 7 | 0 |
| 30 Jun 19 | 5 | -17 | 5 | 0 |
| 31 Mar 19 | 5 | -15 | 3 | 0 |
| 31 Dec 18 | 5 | -13 | 2 | 0 |
| 30 Sep 18 | 3 | -12 | 2 | 0 |
| 30 Jun 18 | 2 | -11 | 2 | 0 |
| 31 Mar 18 | 2 | -8 | 2 | 0 |
| 31 Dec 17 | 2 | -6 | 2 | 0 |
| 30 Sep 17 | 1 | -5 | 1 | 0 |
| 30 Jun 17 | 0 | -5 | 1 | 0 |
| 31 Dec 16 | 0 | -3 | 1 | 0 |
Quality Earnings: BXPH.F is currently unprofitable.
Growing Profit Margin: BXPH.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BXPH.F is unprofitable, but has reduced losses over the past 5 years at a rate of 10.3% per year.
Accelerating Growth: Unable to compare BXPH.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BXPH.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: BXPH.F has a negative Return on Equity (-12.76%), as it is currently unprofitable.